DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$2.57 USD
+0.04 (1.58%)
Updated Apr 26, 2024 03:57 PM ET
After-Market: $2.60 +0.03 (1.17%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DMAC 2.57 +0.04(1.58%)
Will DMAC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DMAC
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
Other News for DMAC
DiaMedica Therapeutics assumed with a Buy at Craig-Hallum
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics says first patient dosed in relaunch of DM199 trial
Diamedica Therapeutics Updates SEC Filing